Mission

Mission

Academic Collaborations

Clinical Lab Accreditations

Nuclea Biotechnologies' primary mission is to conduct genomic research in the oncology field so as to discover biomarkers and gene or protein expression profiles that are unique to oncologic diseases. Nuclea Biotechnologies seeks to harness this knowledge to develop clinically validated molecular diagnostic and pharmacogenomic products and services that can be used, among other things, to provide clinically useful information on the likelihood of recurrence and metastasis of cancer, as well as to predict the likelihood that a patient will respond to a cancer therapy.

Nuclea utilizes a translational medicine-based approach, which allows the conversion of laboratory results into new ways of diagnosing and treating patients. This approach entails using tumor biopsies and associated clinical data to link specific genes and proteins to the characteristics of specific cancers. Information obtained from preliminary human studies can be used to refine understanding of the biological principles underpinning human disease and enable the discovery of disease specific biomarkers and expression profiles. Nuclea's proprietary platform provides a systematically organized basis for collecting an ever-increasing set of tumor biopsy samples coupled with the associated clinical, molecular, and outcomes data, and analyzing the data for insights into the disease. This platform could be described as a virtual clinical trial that can help to predict the response of a specific antibody or compound before pre-clinical trials are complete.

Nuclea Biomarkers is a wholly-owned subsidiary of Nuclea Biotechnologies, LLC

[  back to top  ]